Nerbio is proud to announce the release of iTOF 2.0, the latest version of our FDA-cleared, app-controlled neuromuscular blockade (NMB) monitoring system. This new iteration builds upon the foundational capabilities of iTOF, incorporating advanced features designed to enhance clinical efficiency, patient safety, and user experience.
San Jose, CA — Nerbio, a leader in intelligent patient monitoring solutions, proudly announces that its iTOF® device has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This milestone marks iTOF as the world's first wireless, app-controlled quantitative neuromuscular blockade (NMB) monitoring device to achieve FDA clearance.
Memphis, TN — Nerbio, a fast-growing innovator in app-controlled patient monitoring technology, is proud to announce that it is establishing its U.S. sales operations in Memphis, Tennessee.
San Jose, CA — Nerbio, a global innovator in mobile-based anesthesia and critical care monitoring solutions, today released results from a multi-center case study highlighting the successful clinical adoption of its flagship device, the iTOF®, in over 1,700 surgical cases across India. The study confirms that iTOF—an FDA-cleared, app-controlled neuromuscular monitoring device—is not only clinically effective but highly accepted by anesthesia professionals, overcoming one of the key barriers to widespread adoption of quantitative monitoring in surgery.
